Prothena Corp PLC

PRTA

Company Profile

  • Business description

    Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer’s disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

  • Contact

    77 Sir John Rogerson’s Quay
    Block C
    Grand Canal Docklands
    Dublin 2D02 VK60
    IRL

    T: +353 12362500

    E: [email protected]

    https://www.prothena.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    163

Stocks News & Analysis

stocks

Our top ASX picks in every sector

These companies are our top choices for investors wanting to boost Aussie exposure.
stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,852.2036.900.42%
CAC 407,808.1721.12-0.27%
DAX 4024,160.6494.67-0.39%
Dow JONES (US)44,459.6588.140.20%
FTSE 1008,998.0656.940.64%
HKSE24,250.9047.580.20%
NASDAQ20,640.3354.800.27%
Nikkei 22539,513.4653.840.14%
NZX 50 Index12,691.0012.310.10%
S&P 5006,268.568.810.14%
S&P/ASX 2008,609.2038.800.45%
SSE Composite Index3,486.8832.77-0.93%

Market Movers